Jazz Pharmaceuticals (JAZZ)

[surf1944]

4:15PM Jazz Pharma and Concert Pharmaceuticals announce worldwide licensing agreement to develop and commercialize Deuterium-Modified Sodium Oxybate (JAZZ) 56.83 +0.80 : Co announced an exclusive license agreement that provides Jazz Pharmaceuticals worldwide rights to develop and commercialize Concert's deuterium-modified sodium oxybate (D-SXB) compounds, including C-10323. Under the agreement, Jazz Pharmaceuticals will have worldwide commercial rights to C-10323, as well as principal responsibility for ongoing development activities. Concert will receive an upfront payment and is eligible to receive additional milestone payments as well as tiered royalties based on potential worldwide sales of any D-SXB products.